TRIZAL study: Switching from successful HAART to Trizivir™ (abacavir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence results

Christine Katlama, S. Fenske, B. Gazzard, A. Lazzarin, N. Clumeck, J. Mallolas, A. Lafeuillade, J. P. Mamet, L. Beauvais

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'TRIZAL study: Switching from successful HAART to Trizivir™ (abacavir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence results'. Together they form a unique fingerprint.

Medicine & Life Sciences

Social Sciences